Ixekizumab
Brand: Taltz
Immunomodulator
IL-17A monoclonal antibody
Pharmacokinetics
| Half-life | 13 days |
| Clearance Route | reticuloendothelial |
| Active Metabolites | none |
| Notes | Terminal half-life ~13 days; monthly dosing after loading phase. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Injection site reactions, infections (URTI, candidiasis), neutropenia, inflammatory bowel disease flare
Contraindications:
Active infection
Precautions:
Caution in IBD (may trigger flare); avoid live vaccines